Scholar Rock Holding Corporation (SRRK)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Scholar Rock’s loss per share in the third fiscal quarter of 2026 topped expectations, with EPS of -$0.81 versus the -$0.85 estimate (difference $0.04) when results were reported November 10, 2026. Revenue came in at about $0.6 million, generating roughly $0.6 million of gross profit and a gross margin of ~99%. Operating income was a loss of about $106.1 million, and net income was a loss of roughly $107.2 million, down ~5% year over year from a net loss of about $102.2 million as the company continued advancing its targeted-therapy pipeline, including apitegromab and other TGF-beta–focused programs across neuromuscular disease, cancer, and fibrotic disease research. Consensus for the next period calls for EPS of -$0.68.
About Scholar Rock Holding Corporation
Scholar Rock Holding Corporation develops targeted therapies that modulate protein growth factor signaling as a NASDAQ-listed biotechnology company. The company focuses on precision inhibitors of transforming growth factor beta, or TGF-beta, activation and advances programs in neuromuscular disease, cancer, and fibrotic disease research.
Today's Snapshot
SRRK closed 6.5% higher at 48.00, outperforming a weaker sector. Shares changed hands at about half as much again as its usual level.
Trading Volume
Above 10d avg 2.0M
2.7M
vs S&P 500 Today
Strong Outperformance
+6.74%
Updated: November 18, 2026 at 21:23 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$45.15 - $47.40Buy
- RSI (14)57.31Neutral
- Stochastic %K (14, 3, 3)33.58Neutral
- MACD Level (12, 26)0.35Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.